PMVP

1.44

4.73% 0.065

Dopo l'orario di chiusura: 1.45 0.01 +0.69%

Pmv Pharmaceuticals Inc (PMVP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.375

Aprire:

$1.34

Volume 24 ore:

673.56K

Relative Volume:

1.54

Capitalizzazione di mercato:

$76.98M

Reddito:

Utile/perdita netta:

$-78.34M

Rapporto P/E:

-0.9717

EPS:

-1.4819

Flusso di cassa netto:

$-75.02M

1 W Prestazione:

+16.13%

1M Prestazione:

+17.07%

6M Prestazione:

-11.11%

1 anno Prestazione:

+13.39%

Intervallo 1D:

$1.34

$1.45

Intervallo di 1 settimana:

$1.24

$1.45

Portata 52W:

$1.02

$1.88

Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile

Nome

Pmv Pharmaceuticals Inc

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

(609) 642-6670

Indirizzo

400 ALEXANDER PARK DRIVE, PRINCETON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-20

Ultimi documenti SEC

PMVP's Discussions on Twitter

Compare PMVP vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PMVP Pmv Pharmaceuticals Inc	1.44	73.50M	0	-78.34M	-75.02M	-1.4819
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-08	Aggiornamento	Oppenheimer	Perform → Outperform
2024-05-13	Iniziato	Craig Hallum	Buy
2024-04-12	Iniziato	Jefferies	Buy
2023-12-27	Iniziato	Ladenburg Thalmann	Buy
2022-03-02	Aggiornamento	Oppenheimer	Perform → Outperform
2021-09-22	Aggiornamento	Goldman	Neutral → Buy
2021-08-19	Iniziato	Oppenheimer	Perform
2021-08-02	Iniziato	Guggenheim	Buy
2021-07-29	Iniziato	H.C. Wainwright	Buy
2020-10-20	Iniziato	BofA Securities	Buy
2020-10-20	Iniziato	Cowen	Outperform
2020-10-20	Iniziato	Evercore ISI	Outperform
2020-10-20	Iniziato	Goldman	Neutral

Mostra tutto

Pmv Pharmaceuticals Inc Borsa (PMVP) Ultime notizie

Sep 09, 2026

PMV Pharma appoints Philip Herman as CCO - The Pharma Letter

Sep 09, 2026

Sep 08, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 08, 2026

H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock By Investing.com - Investing.com Nigeria

Sep 08, 2026

H.C. Wainwright reiterates Buy on PMV Pharmaceuticals stock - Investing.com

Sep 08, 2026

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer - Yahoo Finance

Sep 08, 2026

Sep 05, 2026

PMV Pharmaceuticals stock gains as biotech peers advance - ad-hoc-news.de

Sep 05, 2026

Sep 04, 2026

Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - kalkine.ca

Sep 04, 2026

PMV Pharmaceuticals stock gains on HC Wainwright buy rating and 5 dollar target - ad-hoc-news.de

Sep 04, 2026

PMVP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $5.00 - GuruFocus

Sep 04, 2026

Sep 02, 2026

PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering - TipRanks

Sep 02, 2026

Sep 01, 2026

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push - Yahoo Finance

Sep 01, 2026

PMV Pharmaceuticals (PMVP) Announces $50.8M Oversubscribed Offering Amid Mixed Market Signals - GuruFocus

Sep 01, 2026

Aug 31, 2026

PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants - Quiver Quantitative

Aug 31, 2026

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities - GlobeNewswire

Aug 31, 2026

PMV Pharmaceuticals (PMVP) Launches Public Offering Amid Unprofi - GuruFocus

Aug 31, 2026

PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data - TipRanks

Aug 31, 2026

PMV Pharmaceuticals reports 46% ORR in ovarian cohort, plans NDA filing in Q1 2027 - TradingView

Aug 31, 2026

PMV Pharma Announces Proposed Public Offering of Securities - GlobeNewswire

Aug 31, 2026

PMV Pharmaceuticals, Inc. Announces Updated Interim Ovarian Cancer Data for Rezatapopt Monotherapy From PYNNACLE Phase 2 Pivotal Trial - marketscreener.com

Aug 31, 2026

Aug 21, 2026

ETFs Investing in PMV Pharmaceuticals, Inc. Stocks - TradingView

Aug 21, 2026

PMV (PMVP) Watch: Moves 1.15% Higher to $1.31; Price Context: Price Remains Between $1.24 Support and $1.38 Resistance in the Latest SessionValue Factor - vinanet.vn

Aug 21, 2026

Aug 19, 2026

PMV (PMVP) Latest Quarter: The Available Earnings Metric Delivers a Beat in the Latest Reading; Closing Move: The Stock Records a 3.23% Increase on the DayAnalyst Coverage Count - vinanet.vn

Aug 19, 2026

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Aug 19, 2026

Aug 14, 2026

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat

Aug 14, 2026

PMV Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Canada

Aug 14, 2026

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times

Aug 14, 2026

PMV Pharma Reports $18.1 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 14, 2026

PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA - Stock Titan

Aug 14, 2026

PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission - TradingView

Aug 14, 2026

Press Release: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - Moomoo

Aug 14, 2026

Aug 10, 2026